1. Home
  2. GCTK vs LCFY Comparison

GCTK vs LCFY Comparison

Compare GCTK & LCFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GCTK
  • LCFY
  • Stock Information
  • Founded
  • GCTK 2001
  • LCFY 2009
  • Country
  • GCTK United States
  • LCFY Australia
  • Employees
  • GCTK N/A
  • LCFY N/A
  • Industry
  • GCTK Medical/Dental Instruments
  • LCFY
  • Sector
  • GCTK Health Care
  • LCFY
  • Exchange
  • GCTK Nasdaq
  • LCFY Nasdaq
  • Market Cap
  • GCTK 7.6M
  • LCFY 7.3M
  • IPO Year
  • GCTK N/A
  • LCFY 2022
  • Fundamental
  • Price
  • GCTK $0.27
  • LCFY $5.81
  • Analyst Decision
  • GCTK
  • LCFY
  • Analyst Count
  • GCTK 0
  • LCFY 0
  • Target Price
  • GCTK N/A
  • LCFY N/A
  • AVG Volume (30 Days)
  • GCTK 696.8K
  • LCFY 19.4K
  • Earning Date
  • GCTK 11-26-2024
  • LCFY 11-12-2024
  • Dividend Yield
  • GCTK N/A
  • LCFY N/A
  • EPS Growth
  • GCTK N/A
  • LCFY N/A
  • EPS
  • GCTK N/A
  • LCFY N/A
  • Revenue
  • GCTK N/A
  • LCFY $3,169,582.00
  • Revenue This Year
  • GCTK N/A
  • LCFY N/A
  • Revenue Next Year
  • GCTK N/A
  • LCFY N/A
  • P/E Ratio
  • GCTK N/A
  • LCFY N/A
  • Revenue Growth
  • GCTK N/A
  • LCFY N/A
  • 52 Week Low
  • GCTK $0.25
  • LCFY $2.20
  • 52 Week High
  • GCTK $4.95
  • LCFY $11.23
  • Technical
  • Relative Strength Index (RSI)
  • GCTK 21.06
  • LCFY 48.81
  • Support Level
  • GCTK $1.20
  • LCFY $5.54
  • Resistance Level
  • GCTK $1.79
  • LCFY $7.99
  • Average True Range (ATR)
  • GCTK 0.30
  • LCFY 0.47
  • MACD
  • GCTK -0.12
  • LCFY 0.10
  • Stochastic Oscillator
  • GCTK 0.85
  • LCFY 26.60

About GCTK GlucoTrack Inc.

GlucoTrack Inc is a medical device company. It focuses on the design, development, and commercialization of non-invasive glucose monitoring devices for use by people with diabetes and pre-diabetics. The company has developed a non-invasive glucose monitor, the GlucoTrack model DF-F glucose monitoring device, which is designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain, inconvenience, and difficulty of conventional spot finger stick devices. It has completed a feasibility study successfully demonstrating that a minimum two-year implant life is highly probable with the sensor design. They have also initiated an animal study with an initial prototype system that has thus far demonstrated a simple implant procedure and good functionality.

About LCFY Locafy Limited

Locafy Ltd is focused on commercializing its Software as a Service (SaaS) online publishing technology platform. Its platform enables the ability to publish almost any type of content to almost any device that uses a web browser to display web content. The firm has three operating segments: the Publishing segment, the Reseller segment, and the Channel sales segment. It derives a majority of its revenue from Australia and New Zealand.

Share on Social Networks: